During ASMS 2024, which will take place June 2–6, 2024 in Anaheim, California, many scientists are set to present research on the latest advances in mass spectrometry. Recently, LCGC International sat down with Uri Keshet of the University of California, Davis to discuss his presentation, "Metabolomics of 13,700 human plasma samples for the TEDDY cohort: A Big Data Challenge and Opportunity for Mass Spectrometry."
Uri Keshet is the Technical Director at the UC Davis Genome Center - Metabolomics in the University of California, Davis in Davis, California (1). In 2012, he earned his Bachelors in Chemistry, Tel Aviv University, Tel Aviv, Israel, and in 2018, he received a PhD in chemistry from Tel Aviv University as well. His research interests include analytical chemistry, chromatographic separation technologies, development of novel instrumentation, and the development of new methods for MS analysis techniques.
In this interview, Keshet answers the following questions:
To learn more about presentations at ASMS 2024, check out our interviews with Elizabeth Neumann of the University of California, Davis and Nick Riley of the University of Washington.
(1) Uri Keshet. Fiehn Lab 2024. https://fiehnlab.ucdavis.edu/component/contact/contact/11-members/15-cheminformatics-and-compound-id/54 (accessed 2024-5-31)
Navigating the Impact of Funding Cuts: Voices from the Research Community
July 9th 2025Shifts in U.S. federal science funding—driven by the newly established Department of Government Efficiency (DOGE)—are causing delays, uncertainty, and program changes across academic and regulatory research institutions.
FDA Grants Breakthrough Status to AI-Enhanced GC-MS Device for Bladder Cancer Detection
July 1st 2025A new cancer detection test to analyze volatile organic compounds through urine analysis, was granted the Breakthrough Device Designation status by the U.S. FDA. The system, which is built on gas chromatography–mass spectrometry (GC–MS) and proprietary AI, generates real-time cancer risk scores.